200 related articles for article (PubMed ID: 27366948)
1. Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection.
Danziger O; Shai B; Sabo Y; Bacharach E; Ehrlich M
Oncotarget; 2016 Aug; 7(32):52115-52134. PubMed ID: 27366948
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 and Interferon-α Signaling
Danziger O; Pupko T; Bacharach E; Ehrlich M
Front Immunol; 2018; 9():94. PubMed ID: 29441069
[TBL] [Abstract][Full Text] [Related]
3. Lipocalin-2 regulates the expression of interferon-stimulated genes and the susceptibility of prostate cancer cells to oncolytic virus infection.
Barer L; Schröder SK; Weiskirchen R; Bacharach E; Ehrlich M
Eur J Cell Biol; 2023 Jun; 102(2):151328. PubMed ID: 37321037
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S
BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246
[TBL] [Abstract][Full Text] [Related]
5. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression.
Dunn GP; Sheehan KC; Old LJ; Schreiber RD
Cancer Res; 2005 Apr; 65(8):3447-53. PubMed ID: 15833880
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist.
Best SM; Morris KL; Shannon JG; Robertson SJ; Mitzel DN; Park GS; Boer E; Wolfinbarger JB; Bloom ME
J Virol; 2005 Oct; 79(20):12828-39. PubMed ID: 16188985
[TBL] [Abstract][Full Text] [Related]
7. Orf virus inhibits interferon stimulated gene expression and modulates the JAK/STAT signalling pathway.
Harvey R; McCaughan C; Wise LM; Mercer AA; Fleming SB
Virus Res; 2015 Oct; 208():180-8. PubMed ID: 26113305
[TBL] [Abstract][Full Text] [Related]
8. Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus.
Dellac S; Ben-Dov H; Raanan A; Saleem H; Zamostiano R; Semyatich R; Lavi S; Witz IP; Bacharach E; Ehrlich M
Int J Cancer; 2021 May; 148(9):2321-2334. PubMed ID: 33197301
[TBL] [Abstract][Full Text] [Related]
9. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
10. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
11. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.
Dong B; Kim S; Hong S; Das Gupta J; Malathi K; Klein EA; Ganem D; Derisi JL; Chow SA; Silverman RH
Proc Natl Acad Sci U S A; 2007 Jan; 104(5):1655-60. PubMed ID: 17234809
[TBL] [Abstract][Full Text] [Related]
12. Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review.
Chen K; Liu J; Cao X
J Autoimmun; 2017 Sep; 83():1-11. PubMed ID: 28330758
[TBL] [Abstract][Full Text] [Related]
13. Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy.
Ebrahimi S; Ghorbani E; Khazaei M; Avan A; Ryzhikov M; Azadmanesh K; Hassanian SM
J Cell Biochem; 2017 Aug; 118(8):1994-1999. PubMed ID: 28135008
[TBL] [Abstract][Full Text] [Related]
14. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses.
Matveeva OV; Chumakov PM
Rev Med Virol; 2018 Nov; 28(6):e2008. PubMed ID: 30209859
[TBL] [Abstract][Full Text] [Related]
15. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle.
Kawaguchi Y; Miyamoto Y; Inoue T; Kaneda Y
Int J Cancer; 2009 May; 124(10):2478-87. PubMed ID: 19173282
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses.
Li Q; Tainsky MA
PLoS One; 2011; 6(12):e28683. PubMed ID: 22194884
[TBL] [Abstract][Full Text] [Related]
17. Virus Multiplicity of Infection Affects Type I Interferon Subtype Induction Profiles and Interferon-Stimulated Genes.
Zaritsky LA; Bedsaul JR; Zoon KC
J Virol; 2015 Nov; 89(22):11534-48. PubMed ID: 26355085
[TBL] [Abstract][Full Text] [Related]
18. Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism.
Lin RJ; Chang BL; Yu HP; Liao CL; Lin YL
J Virol; 2006 Jun; 80(12):5908-18. PubMed ID: 16731929
[TBL] [Abstract][Full Text] [Related]
19. microRNA control of interferons and interferon induced anti-viral activity.
Sedger LM
Mol Immunol; 2013 Dec; 56(4):781-93. PubMed ID: 23962477
[TBL] [Abstract][Full Text] [Related]
20. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
